CALCULATE YOUR SIP RETURNS

Bajaj Healthcare’s Gujarat Site Gains Australian Approval

Updated on: Dec 9, 2024, 1:59 PM IST
Bajaj Healthcare's Gujarat site gets TGA nod, enabling API exports to Australia & NZ; Q2 FY25 profit rises to ₹94.64 crore, shares up 4.98% at ₹452.95.
Bajaj Healthcare’s Gujarat Site Gains Australian Approval
ShareShare on 1Share on 2Share on 3Share on 4Share on 5

Bajaj Healthcare’s API manufacturing facility in Savli, Vadodara, Gujarat, has received approval from the Therapeutic Goods Administration (TGA) of Australia. This certification, valid for 24 months, permits the direct supply of active pharmaceutical ingredients (APIs) to the Australian and New Zealand markets. The site was already certified by the USFDA and the European Union, ensuring its compliance with global standards.

Expanded Market Access

The TGA approval allows Bajaj Healthcare to supply APIs directly to drug product manufacturers targeting Australia and New Zealand. The company anticipates that this development will attract additional Contract Development and Manufacturing Organization (CDMO) contracts from existing and potential clients. Bajaj Healthcare stated in a regulatory filing that this recognition shows its manufacturing capacity and compliance standards for regulated markets.

Company Overview & Market Reach

Incorporated in 1993, Bajaj Healthcare manufactures APIs, formulations, and nutritional supplements for the pharmaceutical, nutraceutical, and food industries. The company serves over 550 clients globally and exports products to over 62 countries, including Europe, the USA, Africa, and Australia.

Financials

Bajaj Healthcare reported a financial turnaround in Q2 FY25. The company posted a standalone net profit of ₹94.64 crore, an improvement compared to a net loss of ₹34.60 crore in Q2 FY24. Revenue from operations grew by 31.5% year-on-year to ₹133.08 crore. 

As of December 9, 2024, Bajaj Healthcare’s shares are trading at ₹452.95, up by ₹21.50 (4.98%) as of 1:00pm,  with a year-to-date gain of 20.23% and a 23.76% increase over the past year.

With the TGA approval for its Gujarat site, Bajaj Healthcare has expanded its market access to Australia and New Zealand, focusing on global presence. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. It is based on several secondary sources on the internet and is subject to changes. Please consult an expert before making related decisions.

Published on: Dec 9, 2024, 1:59 PM IST

We're Live on WhatsApp! Join our channel for market insights & updates

Open Free Demat Account!

Join our 3 Cr+ happy customers

+91
Enjoy Zero Brokerage on Equity Delivery
4.4 Cr+DOWNLOADS
Enjoy ₹0 Account Opening Charges

Get the link to download the App

Get it on Google PlayDownload on the App Store
Open Free Demat Account!
Join our 3 Cr+ happy customers